Methylated PTGER4 is better than CA125, CEA, Cyfra211 and NSE as a therapeutic response assessment marker in stage IV lung cancer

Zhang,Yunxia; Huang,Jianfeng; Zou,Qinzhou; Che,Jun; Yang,Kaihua; Fan,Qiang; Qian,Danqi; Wu,Jia; Bao,Erwen; Song,Lele; Zhang,Fuzheng

doi:10.3892/ol.2020.11434

Methylated PTGER4 is better than CA125, CEA, Cyfra211 and NSE as a therapeutic response assessment marker in stage IV lung cancer

Authors:
- Yunxia Zhang
- Jianfeng Huang
- Qinzhou Zou
- Jun Che
- Kaihua Yang
- Qiang Fan
- Danqi Qian
- Jia Wu
- Erwen Bao
- Lele Song
- Fuzheng Zhang
View Affiliations

Affiliations: Department of Radiotherapy, The Affiliated Hospital of Jiangnan University, Binhu, Wuxi, Jiangsu 214062, P.R. China, Department of Radiotherapy, The Eighth Medical Center of The Chinese People's Liberation Army General Hospital, Haidian, Beijing 100091, P.R. China
Published online on: March 3, 2020 https://doi.org/10.3892/ol.2020.11434
Pages: 3229-3238
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Real‑time assessment of therapeutic response in patients with advanced lung cancer presents a major challenge throughout the treatment process. Currently, computed tomography imaging is often used; however, it is radiation‑based and hysteretic and is not suitable for repeated use as a real‑time assessment. Blood biomarkers represent a novel solution for assessing therapeutic response in patients with advanced lung cancer. In the present study, the efficacy of a methylation marker [methylated prostaglandin E receptor 4 (mPTGER4)] and four protein markers [carcinoma antigen 125 (CA125), carcinoembryonic antigen (CEA), cytokeratin 19‑fragments (cyfra21‑1) and neuron‑specific enolase (NSE)] were simultaneously evaluated to determine their potential in facilitating therapeutic response monitoring as well as their prognostic values in patients with stage IV lung cancer. The results indicated that, following treatment, the blood levels of methylated PTGER4 and NSE had significantly decreased, and mPRGER4, CA125, CEA and NSE exhibited a significant decrease in percentage level. Since mPTGER4 exhibited a higher rate of positive detection prior to therapy, and a greater response of sensitivity to therapy compared to the protein markers, it may represent an improved marker for the monitoring of therapeutic response. The efficacy of the markers in predicting the overall survival (OS) rate of patients with stage IV lung cancer was also assessed. Results from the follow‑up of patients (up to 891 days) revealed that the blood levels of mPTGER4, CA125 and NSE before treatment were able to predict overall survival (OS) rate. Additionally, the percentage change in expression levels of CA125, CEA and NSE was also able to predict the OS rate. In conclusion, the present results indicate that mPTGER4 represents an improved biomarker for monitoring therapeutic efficacy compared with CA125, CEA, Cyfra21‑1 and NSE. In predicting the long‑term survival of patients with stage IV lung cancer; however, the pre‑treatment levels of mPTGER4, CA125 and NSE and the percentage changes of CA125, CEA and NSE may be used as the markers.

View Figures

View References

1	National Lung Screening Trial Research Team, ; Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS, et al: Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 368:1980–1991. 2013. View Article : Google Scholar : PubMed/NCBI
2	Belloni E, Veronesi G, Rotta L, Volorio S, Sardella D, Bernard L, Pece S, Di Fiore PP, Fumagalli C, Barberis M, et al: Whole exome sequencing identifies driver mutations in asymptomatic computed tomography-detected lung cancers with normal karyotype. Cancer Genet. 208:152–155. 2015. View Article : Google Scholar : PubMed/NCBI
3	Uchida J, Kato K, Kukita Y, Kumagai T, Nishino K, Daga H, Nagatomo I, Inoue T, Kimura M, Oba S, et al: Diagnostic accuracy of noninvasive genotyping of EGFR in lung cancer patients by deep sequencing of plasma cell-free DNA. Clin Chem. 61:1191–1196. 2015. View Article : Google Scholar : PubMed/NCBI
4	Jin X, Chen Y, Chen H, Fei S, Chen D, Cai X, Liu L, Lin B, Su H, Zhao L, et al: Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing. Clin Cancer Res. 23:5311–5319. 2017. View Article : Google Scholar : PubMed/NCBI
5	Leng Q, Lin Y and Jiang F, Lee CJ, Zhan M, Fang H, Wang Y and Jiang F: A plasma miRNA signature for lung cancer early detection. Oncotarget. 8:111902–111911. 2017. View Article : Google Scholar : PubMed/NCBI
6	Ye M, Li S, Huang W, Wang C, Liu L, Liu J, Liu J, Pan H, Deng Q, Tang H, et al: Comprehensive targeted super-deep next generation sequencing enhances differential diagnosis of solitary pulmonary nodules. J Thorac Dis. 10 (Suppl 7):S820–S829. 2018. View Article : Google Scholar : PubMed/NCBI
7	Feng Y, Feng G, Lu X, Qian W, Ye J, Manrique CA, Ma C and Lu Y; written on behalf of the AME Lung Cancer Collaborative Group, : Exploratory analysis of introducing next-generation sequencing-based method to treatment-naive lung cancer patients. J Thorac Dis. 10:5904–5912. 2018. View Article : Google Scholar : PubMed/NCBI
8	Oellerich M, Schütz E, Beck J and Walson PD: Circulating cell-free DNA-diagnostic and prognostic applications in personalized cancer therapy. Ther Drug Monit. 41:115–120. 2019. View Article : Google Scholar : PubMed/NCBI
9	Lim M, Kim CJ, Sunkara V, Kim MH and Cho YK: Liquid biopsy in lung cancer: Clinical applications of circulating biomarkers (CTCs and ctDNA). Micromachines (Basel). 9:E1002018. View Article : Google Scholar : PubMed/NCBI
10	Mayo-de-Las-Casas C, Garzón Ibáñez M, Jordana-Ariza N, García-Peláez B, Balada-Bel A, Villatoro S, Malapelle U, Karachaliou N, Troncone G, Rosell R and Molina-Vila MA: An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. Expert Rev Mol Diagn. 18:35–45. 2018. View Article : Google Scholar : PubMed/NCBI
11	Weiss G, Schlegel A, Kottwitz D, König T and Tetzner R: Validation of the SHOX2/PTGER4 DNA methylation marker panel for plasma-based discrimination between patients with malignant and nonmalignant lung disease. J Thorac Oncol. 12:77–84. 2017. View Article : Google Scholar : PubMed/NCBI
12	Chu X, Zhao W and Wang B: DNA methylation detection of SHOX2 and PTGER4 in plasma contributes to differential diagnosis of pulmonary nodule patients. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 35:357–361. 2019.(In Chinese). PubMed/NCBI
13	Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, et al: Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 15:504–535. 2017. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Schmidt B, Beyer J, Dietrich D, Bork I, Liebenberg V and Fleischhacker M: Quantification of cell-free mSHOX2 Plasma DNA for therapy monitoring in advanced stage non-small cell (NSCLC) and small-cell lung cancer (SCLC) patients. PLoS One. 10:e01181952015. View Article : Google Scholar : PubMed/NCBI
16	Peng XM, Liu XL, Xu L, Li Y, Wang H, Song L and Xiao W: The mSHOX2 is capable of assessing the therapeutic effect and predicting the prognosis of stage IV lung cancer. J Thor Dis. 11:2458–2469. 2019. View Article : Google Scholar
17	Duffy MJ and O'Byrne K: Tissue and blood biomarkers in lung cancer: A review. Adv Clin Chem. 86:1–21. 2018. View Article : Google Scholar : PubMed/NCBI
18	Yang B, Li X, Ren T and Yin Y: Autoantibodies as diagnostic biomarkers for lung cancer: A systematic review. Cell Death Discov. 5:1262019. View Article : Google Scholar : PubMed/NCBI
19	Qin J, Zeng N, Yang T, Wan C, Chen L, Shen Y and Wen F: Diagnostic value of autoantibodies in lung cancer: A systematic review and meta-analysis. Cell Physiol Biochem. 51:2631–2646. 2018. View Article : Google Scholar : PubMed/NCBI
20	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
21	Epi proLung. Instruction for use. Epigenomics AG; Berlin: 2018, https://www.epigenomics.com/wp-content/uploads/2018/08/IFU_0018_GB_rev4_Instructions_for_Use_Epi_proLung.pdfAugust 6–2018
22	Song L, Guo S, Wang J, Peng X, Jia J, Gong Y, Yang B, Xiao W, Dong C, Liu H and Li Y: The blood mSEPT9 is capable of assessing the surgical therapeutic effect and the prognosis of colorectal cancer. Biomark Med. 12:961–973. 2018. View Article : Google Scholar : PubMed/NCBI
23	Song L, Yu H, Jia J and Li Y: A systematic review of the performance of the SEPT9 gene methylation assay in colorectal cancer screening, monitoring, diagnosis and prognosis. Cancer Biomark. 18:425–432. 2017. View Article : Google Scholar : PubMed/NCBI
24	Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD and Knippers R: DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61:1659–1665. 2001.PubMed/NCBI
25	Dietrich D, Hasinger O, Liebenberg V, Field JK, Kristiansen G and Soltermann A: DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. Diagn Mol Pathol. 21:93–104. 2012. View Article : Google Scholar : PubMed/NCBI
26	Bergheim J, Semaan A, Gevensleben H, Groening S, Knoblich A, Dietrich J, Weber J, Kalff JC, Bootz F, Kristiansen G and Dietrich D: Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: A prospective observational cohort study. Br J Cancer. 118:1217–1228. 2018. View Article : Google Scholar : PubMed/NCBI
27	Song L, Jia J, Yu H, Peng X, Xiao W, Gong Y, Zhou G, Han X and Li Y: The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location. J Cancer Res Clin Oncol. 143:1093–1101. 2017. View Article : Google Scholar : PubMed/NCBI
28	Song L, Jia J, Peng X, Xiao W and Li Y: The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis. Sci Rep. 7:30322017. View Article : Google Scholar : PubMed/NCBI
29	Wang H, Shen L, Geng J, Wu Y, Xiao H, Zhang F and Si H: Prognostic value of cancer antigen −125 for lung adenocarcinoma patients with brain metastasis: A random survival forest prognostic model. Sci Rep. 8:56702018. View Article : Google Scholar : PubMed/NCBI
30	Isaksson S, Jönsson P, Monsef N, Brunnström H, Bendahl PO, Jönsson M, Staaf J and Planck M: CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma. PLoS One. 12:e01862842017. View Article : Google Scholar : PubMed/NCBI
31	Grunnet M and Sorensen JB: Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 76:138–143. 2012. View Article : Google Scholar : PubMed/NCBI
32	Yu Z, Zhang G, Yang M, Zhang S, Zhao B, Shen G and Chai Y: Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in non-small cell lung cancer: A meta-analysis. Oncotarget. 8:4043–4050. 2017.PubMed/NCBI
33	Xue F, Zhu L, Wang L and Wang Q: Serum neuron specific enolase levels correlate with patient prognosis for advanced lung cancer. Int J Clin Exp Med. 8:9498–9504. 2015.PubMed/NCBI
34	Liu X, Zhang W, Yin W, Xiao Y, Zhou C, Hu Y and Geng S: The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy. Medicine (Baltimore). 96:e82582017. View Article : Google Scholar : PubMed/NCBI
35	Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, et al: NCCN guidelines insights: Small cell lung cancer, version 2.2018. J Natl Compr Canc Netw. 16:1171–1182. 2018. View Article : Google Scholar : PubMed/NCBI
36	Roviello G: The distinctive nature of adenocarcinoma of the lung. Onco Targets Ther. 8:2399–2406. 2015. View Article : Google Scholar : PubMed/NCBI
37	Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 37:537–546. 2019. View Article : Google Scholar : PubMed/NCBI
38	Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, et al: Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 379:2040–2051. 2018. View Article : Google Scholar : PubMed/NCBI
39	Ravegnini G, Zolezzi Moraga JM, Maffei F, Musti M, Zenesini C, Simeon V, Sammarini G, Festi D, Hrelia P and Angelini S: Simultaneous analysis of SEPT9 promoter methylation status, micronuclei frequency, and folate-related gene polymorphisms: The potential for a novel blood-based colorectal cancer biomarker. Int J Mol Sci. 16:28486–28497. 2015. View Article : Google Scholar : PubMed/NCBI
40	Ma Y, Chen Y and Petersen I: Expression and promoter DNA methylation of MLH1 in colorectal cancer and lung cancer. Pathol Res Pract. 213:333–338. 2017. View Article : Google Scholar : PubMed/NCBI
41	Tan SX, Hu RC, Liu JJ, Tan YL and Liu WE: Methylation of PRDM2, PRDM5 and PRDM16 genes in lung cancer cells. Int J Clin Exp Pathol. 7:2305–2311. 2014.PubMed/NCBI